GlassScriptPhysician profile
Jahan Aghalar
NPI 1346474517
$271,141.76
in general payments reported to CMS, 2019-2025
25 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $30K · 2021: $29K · 2022: $62K · 2023: $65K · 2024: $21K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $103K · Consulting Fee: $13K · Travel and Lodging: $11K · Honoraria: $1,715 · Food and Beverage: $889 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,784.07 |
| Consulting Fee | $12,654.25 |
| Travel and Lodging | $10,553.74 |
| Honoraria | $1,715.00 |
| Food and Beverage | $888.54 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $86,986.75 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $63,780.15 | 2019-2025 | |
| Emd Serono, INC. | $51,400.09 | 2020-2025 | Bavencio |
| Pfizer INC. | $45,685.14 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $15,044.84 | 2023-2025 | Keytruda |
| Exelixis INC. | $2,516.94 | 2024 | Cabometyx |
| Clovis Oncology, INC. | $2,055.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,040.42 | 2019-2025 | |
| Genzyme Corporation | $850.00 | 2020 | |
| Janssen Scientific Affairs, LLC | $757.50 | 2022 | |
| Abbott Laboratories | $282.69 | 2022-2023 | Freestyle Libre 3 |
| Dendreon Pharmaceuticals LLC | $174.83 | 2024 | Provenge |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Amgen INC. | $125.00 | 2025 | Otezla |
| Cti Biopharma Corp. | $68.63 | 2023 | Vonjo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $49.94 | 2020 | |
| Lilly USA, LLC | $46.56 | 2020 | |
| Astellas Pharma US INC | $32.84 | 2019-2022 | |
| Tactile Systems Technology INC | $22.96 | 2021 | |
| Sirtex Medical INC | $20.77 | 2022-2023 | Sir-Spheres Microspheres |
| Seagen INC. | $18.78 | 2020 | |
| Blue Earth Diagnostics | $17.05 | 2021 | |
| Eisai INC. | $16.90 | 2023 | |
| Celgene Corporation | $11.50 | 2019 | |
| Ge Healthcare | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jahan Aghalar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.